This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Alert me to new issues of the journal Download to citation manager Reprints and Permissions Copyright Information Books from ASM Press MicrobeWorld Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Mason, R. A. Articles by Trimmer, R. W. Search for Related Content PubMed Articles by Mason, R. A. Articles by Trimmer, R. W. Agricola Articles by Mason, R. A. Articles by Trimmer, R. W.

 Previous Article  |  Next Article 

Appl Environ Microbiol. 1972 May; 23(5): 908-913
Copyright © 1972 American Society for Microbiology. All Rights Reserved.

Yellow Fever Vaccine. V. Antibody Response in Monkeys Inoculated with Graded Doses of the 17D Vaccine

¹ Laboratory of Virology and Rickettsiology, Division of Biologics Standards, National Institutes of Health, Bethesda, Maryland 20014

ABSTRACT

A dosage equal to or greater than approximately 3.4 Dex (decimal exponent, log₁₀) weanling mouse intracerebral 50% lethal dose (LD₅₀) was sufficient to elicit a yellow fever antibody response, as determined by the plaque neutralization (PN) test, in better than 90% of vaccinated rhesus monkeys. Lower dosages were progressively less effective in terms of PN titers and the PN and hemagglutination-inhibition serological conversion rates observed. A dose of between 3.4 and 4.2 Dex weanling mouse intracerebral LD₅₀, or one-tenth to one times the dosage recommended for man, provided an optimal antibody response in monkeys. In rhesus monkeys, in contrast to the findings for man, pre-existing yellow fever antibody did not interfere with the antibody response to yellow fever vaccine. The PN test was felt to be a more sensitive and specific indicator of yellow fever antibody in rhesus monkeys after vaccination than the hemagglutination inhibition or complement fixation tests.